diacerein / Generic mfg. - LARVOL DELTA

AIM2 Inflammasome-Mediated Chondrocyte Pyroptosis in Knee Osteoarthritis and the Intervention of Wangbi Formula Combined with Diacerein (ACR Convergence 2026) - No abstract available

Immunology • Osteoarthritis • Rheumatology

A Randomized Controlled Trial: Efficacy of Wangbi Capsule Plus Conventional Therapy for Knee Osteoarthritis and Its Modulation of the Ferroptosis Pathway. (PubMed, Curr Rheumatol Rev) - "WBC plus conventional therapy improved symptoms safely over 12 weeks; its ferroptosis-related effects await verification in dedicated mechanistic studies."

Journal • Immunology • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • ACSL4 • GPX4 • SLC7A11

The effects of 2-year SYSADOA treatment on glycemic level in patients with comorbid primary knee osteoarthritis and type 2 diabetes mellitus. (PubMed, J Diabetes Metab Disord) - "To evaluate the effects of long-term use of symptomatic slow-acting drugs for osteoarthritis (SYSADOA), including glucosamine and diacerein, on glycemic control in patients with knee osteoarthritis (KOA) and type 2 diabetes mellitus (T2DM)...SYSADOA use was not associated with clinically meaningful changes in glycemic control over 24 months in patients with KOA and T2DM. The online version contains supplementary material available at https://doi.org/10.1007/s40200-026-02069-1."

Journal • Diabetes • Immunology • Metabolic Disorders • Osteoarthritis • Pain • Rheumatology • Type 2 Diabetes Mellitus

A Comparison of Clinical Outcomes Among Undenatured Collagen Type II, Glucosamine Sulfate, and Diacerein on Osteoarthritic Knee Treatment: A Randomized Clinical Trial. (PubMed, JB JS Open Access) - "Thailand Clinical Trial Registry (TCTR20210901003). Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence."

Clinical • Clinical data • Journal • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology

Diacerein Protects Against Obesity-Related Cardiovascular Injury: Evidence from In Silico and In Vivo Studies. (PubMed, Appl Biochem Biotechnol) - "Diacerein treatment markedly alleviated metabolic abnormalities, diminished cardiac injury and systemic inflammation, improved histological features, and reduced tissue protein levels of the TLR4/NF-κB pathway and pro-inflammatory cytokines. In conclusion, diacerein provides marked protection against obesity-induced cardiovascular injury, at least partially, by inhibiting the TLR4/NF-κB inflammatory pathway, supporting its potential as a therapeutic strategy for obesity-related cardiovascular complications."

Journal • Preclinical • Cardiovascular • Dyslipidemia • Genetic Disorders • Immunology • Inflammation • Metabolic Disorders • Obesity • Osteoarthritis • Pain • Rheumatology • CRP • IL6 • IRAK1 • MYD88 • PTPRC • TNFA • TRAF6

Rhein alleviates lethal renal ischemia-reperfusion injury via inhibition of NLRP3 inflammasomes by targeting PPARγ. (PubMed, Biochem Pharmacol) - "Rhein, an anthraquinone-derivative monomer isolated from the rhubarb plant, is the active ingredient of the drug Diacerein® (generic name: diacetylrhein), which possesses anti-inflammatory and antioxidant properties...This protection is mainly achieved by targeting and enhancing the expression of PPARγ, thereby inhibiting the activation of the NLRP3 inflammasome. Thus, rhein may be therapeutically useful for the clinical prevention and treatment of renal IRI."

Journal • Cardiovascular • Inflammation • Reperfusion Injury • CASP1 • IL1B • NLRP3 • PPARG

Discovery of a novel twin drug from Phillygenin and glucosamine for osteoarthritis treatment. (PubMed, Bioorg Chem) - "In particular, it displayed comparable therapeutic efficacy and more favorable safety profiles compared to the clinically-used diacerein (DIA) and functions via multiple cellular mechanisms ranging from osteoclast differentiation inhibition and anti-inflammation/anti-oxidation to cartilage protection. Overall, our findings highlight 6 as a promising candidate for anti-OA drug discovery."

Journal • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology

Network meta-analysis comparing the efficacy of subsequent treatment regimens in primary immune thrombocytopenia patients (ISTH 2026) - "In placebo- controlled studies, Romiplostim showed the highest efficacy, followed by Hetrombopag, Eltrombopag, Fostamatinib, and Rilzabrutinib. In studies using Danazol as the control, ATRA plus danazol had the highest efficacy, followed by Tacrolimus plus danazol and rhTPO plus danazol. In studies using Eltrombopag as the control, the Eltrombopag plus diacerein regimen was more effective than rhTPO. Conclusions These results furnish high-quality evidence to support evidence-based, individualized selection of subsequent therapy for adults with relapsed/refractory primary immune thrombocytopenia. Table or Figure Upload (1) Figure 1.Network meta-analysis comparing the efficacy of subsequent treatment regimens Page 2 DOI*10.1016/j.rpth.2026.104395"

Retrospective data • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

Innovative rhein and hydroxy fatty acid ester prodrugs for the treatment of chronic inflammation. (PubMed, Phytomedicine) - "Overall, our novel rhein-hydroxy fatty acid ester prodrugs are promising candidates for chronic inflammation in clinical therapy. This study might reveal an avenue to develop rhein hydroxy fatty acid ester prodrugs with satisfactory pharmacological activity to resolve various inflammatory diseases."

Journal • Cardiovascular • Diabetes • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hepatology • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Oncology • Rheumatology • TLR4

Co-assembly of dipeptide and hydrophobic drug in hyaluronic acid through Schiff base reaction for the treatment of osteoarthritis. (PubMed, Pharm Sci Adv) - "This carrier is designed to encapsulate hydrophobic nonsteroidal anti-inflammatory drug (NSAID) celecoxib and IL-1β inhibitor diacerein via a one-step co-assembly method, facilitating targeted drug delivery and combination therapy for OA. In a rat OA model, intra-articular administration of these co-assembled materials significantly suppressed inflammatory cytokines (TNF-α, IL-1β, and PGE2) and demonstrated enhanced cartilage repair by integrating multiple functions of hydrophilic HA, supramolecular carriers, and hydrophobic drugs. This work established a simple strategy for co-assembly of biomolecules and hydrophobic drug molecules and holds significant clinical promise for the treatment of OA."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology • IL1B • TNFA

Diacerein Ameliorates Gentamicin-Induced Nephrotoxicity via Regulating PI3k/AKT-Mediated Nrf-2 and NF-κB Pathways: Forge the Mechanistic Insight. (PubMed, J Biochem Mol Toxicol) - "DIA exhibits renal protection in GM-induced nephrotoxicity mainly through modulating PI3K/AKT/Nrf2 signaling pathways. PCA and SEM analyses provide novel mechanistic and diagnostic insights that enhance the translational potential of the findings."

Journal • Inflammation • CASP3 • CAT

Statistical optimization and characterization of diacerein-loaded Eudragit S-100 nanoparticles using a 32 factorial design for rheumatoid arthritis therapy. (PubMed, Ther Deliv) - "The in-vitro studies show that when using diacerein delivered through nanoparticles, there will be a greater anti-inflammatory response from chondrocytes than if diacerein were administered alone. Therefore, this study provides evidence that nanoparticles can be used to treat RA, improving drug effectiveness, decreasing systemic toxicity, and improving patient compliance."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Diacerein Disrupts Testicular Homeostasis: The Essential Role of Basal Cytokines in Maintaining Sertoli Cell Integrity and the Immune Microenvironment. (PubMed, Andrology) - "Basal cytokines are essential for SC structure and function. Despite testicular damage, diacerein shifted the immune response toward a homeostatic and immunotolerant profile, avoiding a self-destructive inflammatory process."

Journal • CD68 • CLDN1 • IL1B • LDHA • NOS2 • PTPRC • TGFB1 • TNFA • VIM

Diacerein mitigates cisplatin-induced testicular toxicity in rats; Role of Nrf2/ HO-1, NF-κB/caspase-3 and NLRP3/ASC/Caspase-1 signaling pathways. (PubMed, Mol Biol Rep) - "DIA exerts a protective effect against CIS-induced testicular toxicity through its antioxidant, anti-inflammatory, and anti-pyroptotic activities, highlighting its potential as a therapeutic candidate targeting the Nrf2/HO-1, NF-κB, and NLRP3/ASC/caspase-1 signaling pathways."

Journal • Preclinical • Inflammation • CASP3 • IL1B • NLRP3 • TNFA

Diacerein alleviates endometrial fibrosis in an intrauterine adhesion model via ferroptosis inhibition. (PubMed, Exp Anim) - "Mechanistically, diacerein modulated the NRF2/HMGB1 signaling pathway, restoring NRF2 and HO1 levels while downregulating HMGB1 expression. Collectively, these findings suggest that diacerein effectively attenuates ferroptosis-mediated fibrosis in IUA, highlighting ferroptosis inhibition as a promising therapeutic strategy for IUA management."

Journal • Fibrosis • Immunology • Infertility • Sexual Disorders • ACSL4 • CDH1 • CDH2 • CK19 • GPX4 • HMGB1 • KRT19 • SLC7A11

Diacerein protects against thioacetamide-induced acute liver injury via modulating HMGB1/TLR4/MyD88/NF-κB signaling pathway. (PubMed, Toxicol Appl Pharmacol) - "For the treatment groups, rats were pretreated orally for six days prior to TAA administration; NAC + TAA group received N-acetylcysteine (50 mg/kg), followed by a single intraperitoneal injection of TAA (500 mg/kg) on day 6. Moreover, diacerein markedly (p ≤ 0.05) reduced inflammation by down-regulating HMGB1/TLR4/MYD88/NF-κB signaling pathway. Collectively, diacerein might be a potential therapeutic candidate for treatment of ALI pending further clinical studies to confirm this notion."

Journal • Hepatology • Inflammation • Liver Failure • HMGB1 • MYD88 • TLR4

Insights Into the Ameliorative Effect of Diacerein on Cyclophosphamide-Induced Testicular Toxicity: Targeting TLR4/NF-κB/IL-1β Pathway. (PubMed, J Biochem Mol Toxicol) - "Moreover, DIA abrogated CYP-provoked apoptosis, as evident by down-regulated cleaved-caspase-3 expression. In summary, the results of this investigation reported that DIA's antioxidant, anti-inflammatory, and antiapoptotic impact mediated its protective influence against CYP-induced male organ toxicity."

IO biomarker • Journal • Immunology • Infertility • Inflammation • Osteoarthritis • Pain • Rheumatology • Sexual Disorders • CASP3 • IL1B • TLR4

Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis. (clinicaltrials.gov) - P3 | N=123 | Completed | Sponsor: Laboratorios Liomont

New P3 trial • Immunology • Osteoarthritis • Pain • Rheumatology

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (clinicaltrials.gov) - P2/3 | N=80 | Active, not recruiting | Sponsor: TWi Biotechnology, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • KRT14 • KRT5

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study with Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (ChiCTR) - P2/3 | N=100 | Sponsor: Dematology Hospital of Southern Medical University; Dematology Hospital of Southern Medical University

New P2/3 trial • KRT14 • KRT5

Clinical Efficacy of Oral Diacerein in Ameliorating Chronified Pain and Delaying Tendon Degeneration in Rotator Cuff Injury (ChiCTR) - P=N/A | N=192 | Sponsor: The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology

New trial • Pain

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) (clinicaltrials.gov) - P2/3 | N=80 | Recruiting | Sponsor: TWi Biotechnology, Inc. | Trial primary completion date: Mar 2026 ➔ Sep 2026

Trial primary completion date • KRT14 • KRT5

Retraction Note: Diacerein ameliorates amiodarone-induced pulmonary fibrosis via targeting the TGFβ1/α-SMA/Smad3 pathway. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - No abstract available

Journal • Immunology • Pulmonary Disease • Respiratory Diseases • SMAD3 • TGFB1

Intra-articular dual-targeted hydrogel co-delivering diacerein nanoparticles and ketorolac for modulating neuroimmune interplay and cartilage degeneration in osteoarthritis. (PubMed, Drug Deliv Transl Res) - "In conclusion, embedding SLN within an injectable hydrogel enabled targeted, site-specific, and sustained intra-articular drug delivery, reducing systemic exposure while enhancing efficacy. These results demonstrate the DC-SLN gel as a promising translational platform that unites targeted pain management with disease-modifying potential for advanced OA therapy."

Journal • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology • CCL2 • CD68 • IL1B • MIR140 • MMP13

Emodin and the Anthraquinone Scaffold: Therapeutic Promise and Strategies to Overcome Translational Barriers. (PubMed, Molecules) - "The present review integrates pharmacological, toxicological, and formulation-focused evidence to provide a unified assessment of emodin and the anthraquinone scaffold. Particular emphasis is placed on bidirectional, dose- and context-dependent effects on the liver and kidney; the modulation of cytochrome P450 enzymes, UGTs, and transporters; and emerging preclinical formulation strategies that aim to decouple intrinsic bioactivity from pharmacokinetic limitations."

Journal • Review • Cardiovascular • Gastrointestinal Disorder • Immunology • Oncology • AMPK • NLRP3